Leonteq Securities’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Leonteq Securities's NBIX Position: Q3 2026 in Review
Leonteq Securities reduced its Neurocrine Biosciences (NBIX) stake by 20% in Q3 2026, selling an estimated $12.7K and leaving 315 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #797.
Leonteq Securities first reported a position in NBIX in Q4 2020 and has held it in 23 quarters since. The position peaked at $537K in Q1 2021. 642 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Leonteq Securities held 315 shares of Neurocrine Biosciences worth $44.7K as of Q3 2026.
- Leonteq Securities sold 79 Neurocrine Biosciences shares in Q3 2026, an estimated $12.7K.
- Neurocrine Biosciences made up ﹤0.01% of Leonteq Securities's portfolio in Q3 2026, its #797 holding.
- Leonteq Securities first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 23 quarters since.
- Leonteq Securities's Neurocrine Biosciences position peaked at $537K in Q1 2021.
- 642 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.